Meeting to be held in Boston on April 8 and in New York on April 9 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM ...

BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...